The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents
- PMID: 37097079
- PMCID: PMC10437036
- DOI: 10.3238/arztebl.m2023.0079
The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents
Abstract
Background: Osteosarcoma and Ewing's sarcoma in children and adolescents require age-specific interdisciplinary diagnosis and treatment to achieve optimal therapeutic outcomes.
Methods: The diagnosis and treatment of malignant bone tumors in childhood and adolescence are presented in the light of publications retrieved by a selective search, pertinent guidelines, and the authors' extensive experience in an interdisciplinary cancer center.
Results: Bone sarcomas make up approximately 5% of all malignancies in children and adolescents; the most common types are Ewing's sarcoma and osteosarcoma. Patients are often not referred to a specialized center until long after the onset of symptoms, as they and their physicians rarely consider the possibility of a bone tumor, and the symptoms are often trivialized. Bone pain of unknown origin, swelling, and functional limitations should be investigated with conventional x-rays. Lesions of unclear origin should be biopsied after a meticulous clinical and radiologic evaluation. Multimodal treatment consists of neo - adjuvant chemotherapy, limb-preserving resection if possible, and radiotherapy where indicated. In multicenter studies, patients with osteosarcoma achieve event-free survival in 64% of cases if their disease is localized, and 28% if it is metastatic; the corresponding figures for patients with Ewing's sarcoma are 80% and 27%, respectively.
Conclusion: With implementation of the current treatment recommendations, most children and adolescents with malignant bone tumors can be treated successfully with curative intent. These patients should be referred to a sarcoma center for diagnosis and treatment.
Figures

Similar articles
-
[Osteosarcoma and Ewing's sarcoma--The most frequent malignant bone tumors in children--therapy and outcome].Z Orthop Ihre Grenzgeb. 2002 Nov-Dec;140(6):652-5. doi: 10.1055/s-2002-36040. Z Orthop Ihre Grenzgeb. 2002. PMID: 12476389 German.
-
Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.Clin Orthop Relat Res. 2020 Feb;478(2):290-302. doi: 10.1097/CORR.0000000000000962. Clin Orthop Relat Res. 2020. PMID: 31580267 Free PMC article.
-
Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.J Natl Compr Canc Netw. 2007 Apr;5(4):449-55. doi: 10.6004/jnccn.2007.0039. J Natl Compr Canc Netw. 2007. PMID: 17442235 Review.
-
[Treatment of pelvic Ewing's sarcoma in children and the effect on the skeletal growth and development].Zhonghua Zhong Liu Za Zhi. 2012 Dec;34(12):927-31. doi: 10.3760/cma.j.issn.0253-3766.2012.12.010. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23336380 Chinese.
-
The value of adjuvant chemotherapy in the management of sarcomas in children.Cancer. 1985 May 1;55(9 Suppl):2184-97. doi: 10.1002/1097-0142(19850501)55:9+<2184::aid-cncr2820551422>3.0.co;2-n. Cancer. 1985. PMID: 3884137 Review.
Cited by
-
Targeting nerve growth factor-mediated osteosarcoma metastasis: mechanistic insights and therapeutic opportunities using larotrectinib.Cell Death Dis. 2024 May 30;15(5):381. doi: 10.1038/s41419-024-06752-0. Cell Death Dis. 2024. PMID: 38816365 Free PMC article.
-
Identification and validation of HOXC6 as a diagnostic biomarker for Ewing sarcoma: insights from machine learning algorithms and in vitro experiments.Front Immunol. 2025 Apr 4;16:1449355. doi: 10.3389/fimmu.2025.1449355. eCollection 2025. Front Immunol. 2025. PMID: 40255403 Free PMC article.
-
Unlocking epigenetics for precision treatment of Ewing's sarcoma.Chin J Cancer Res. 2024 Jun 30;36(3):322-340. doi: 10.21147/j.issn.1000-9604.2024.03.08. Chin J Cancer Res. 2024. PMID: 38988487 Free PMC article.
-
Disease burden and trends of malignant neoplasm of bone and articular cartilage in childhood in China, 1990-2021 and comparison with United States and India: findings from the Global Burden of Disease Study 2021.Front Public Health. 2025 Jul 3;13:1481304. doi: 10.3389/fpubh.2025.1481304. eCollection 2025. Front Public Health. 2025. PMID: 40678654 Free PMC article.
-
A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.Discov Oncol. 2025 Feb 28;16(1):255. doi: 10.1007/s12672-025-02007-2. Discov Oncol. 2025. PMID: 40019638 Free PMC article.
References
-
- Erdmann FKP, Grabow D, Spix C. German Childhood Cancer Registry—Annual Report 2019 (1980-2018) Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University. 2020
-
- (WHO) WHOCoTEB. WHO. Lyon, France: 2020. WHO classification of tumours. Soft tissue and bone tumors. 5th edition Volume 3. International Agency for Research on Cancer.
-
- Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30:425–430. - PubMed
-
- Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790. - PubMed
-
- Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010;28:1982–1988. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical